1. US Food and Drug Administration. FDA workshop: clinical trial design for non-muscle invasive bladder cancer (NMIBC). November 18–19, 2021. https://www.fda.gov/drugs/news-events-human-drugs/fda-workshop-clinical-trial-design-non-muscle-invasive-bladder-cancer-nmibc-11182021.
2. Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study;Catto;J Clin Oncol,2021
3. Black PC, Tangen CM, Singh P, et al. Phase 2 Trial of atezolizumab in bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive bladder cancer: SWOG S1605. Eur Urol. 2023;84:535–44. https://doi.org/10.1016/j.eururo.2023.08.004.
4. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021
5. Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group;Kamat;J Clin Oncol,2016